Certified by Founder Lodge
Janus Henderson Investors
United Kingdom - London
INVESTOR
1 Disclosed Funding Rounds $200,000,000
10 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Janus Henderson Investors exists to help clients achieve their long-term financial goals.
Formed in 2017 from the merger between Janus Capital Group and Henderson Global Investors, we are
Company | Date | Round | Raised |
---|---|---|---|
Asher Biotherapeutics | April, 17 ,2024 | Series C | $55,000,000 |
CARGO Therapeutics | March, 06 ,2023 | Series A | $200,000,000 |
Alpha-9 Oncology | October, 24 ,2024 | Series C | $175,000,000 |
Bicara Therapeutics | March, 07 ,2023 | Series B | $108,000,000 |
Metsera | November, 14 ,2024 | Series B | $215,000,000 |
Parse Biosciences | February, 15 ,2022 | Series B | $41,500,000 |
HeartFlow, Inc | April, 07 ,2023 | Series F | $215,000,000 |
Asher Biotherapeutics | April, 17 ,2024 | Series C | $55,000,000 |
Alpha-9 Oncology | October, 24 ,2024 | Series C | $175,000,000 |
Metsera | November, 14 ,2024 | Series B | $215,000,000 |